Biogen (BIIB) PT Lowered to $272 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Biogen (BIIB) PT Lowered to $423 at Mizuho Securities
April 30, 2018 1:01 AM EDTMizuho Securities lowered its price target on Biogen (NASDAQ: BIIB) to $423.00 (from $433.00) while maintaining a Buy rating.
... MoreBiogen (BIIB): Mixed Results Keep Shares Steady For Now - Nomura
April 25, 2018 8:50 AM EDTNomura/Instinet analyst, Christopher Marai, reiterated his Buy rating on shares of Biogen (NASDAQ: BiIB) after the company reported 1Q18 results, with revenue of $3.13bn missing consensus of $3.15bn, but beat on the bottom line EPS of $6.05 vs. consensus of $5.93.
1Q highlighted an... More
Biogen (BIIB) PT Lowered to $311 at RBC Capital
April 25, 2018 7:43 AM EDTRBC Capital lowered its price target on Biogen (NASDAQ: BIIB) to $311.00 (from $316.00) while maintaining a Sector Perform rating.
Analyst Brian Abrahams said Q1 softness stems from Spinraza and seasonality.
... MoreBiogen (BIIB) PT Raised to $369 at Morgan Stanley
April 25, 2018 7:24 AM EDTMorgan Stanley raised its price target on Biogen (NASDAQ: BIIB) to $369.00 (from $365.00) while maintaining a Overweight rating.
... MoreBiogen (BIIB) PT Lowered to $375 at Oppenheimer
April 25, 2018 7:15 AM EDTOppenheimer lowered its price target on Biogen (NASDAQ: BIIB) to $375.00 (from $400.00) while maintaining a Outperform rating.
Analyst Jay Olson commented, "A solid 1Q update addressed investor concerns on multiple fronts with decent financial results featuring an EPS beat of $6.05 vs $5.93E consensus and... More
Biogen (BIIB) PT Lowered to $325 at Leerink Partners
April 25, 2018 6:37 AM EDTLeerink Partners lowered its price target on Biogen (NASDAQ: BIIB) to $325.00 (from $365.00) while maintaining a Market Perform rating.
... MoreBiogen (BIIB) PT Lowered to $385 at Guggenheim
April 25, 2018 2:03 AM EDTGuggenheim lowered its price target on Biogen (NASDAQ: BIIB) to $385.00 (from $400.00) while maintaining a Buy rating.
... MoreUPDATE: Baird Upgrades Biogen (BIIB) to Outperform
April 25, 2018 1:08 AM EDT(Updated - April 25, 2018 4:37 AM EDT)
(updated to add analyst comment)
Baird upgraded Biogen (NASDAQ: BIIB) from Neutral to Outperform with a price target of $323.00.
Analyst Brian Skorney comments "While we have all the enthusiasm that goes with... More
UPDATE: Goldman Sachs Downgrades Biogen (BIIB) to Buy
April 25, 2018 12:56 AM EDT(Updated - April 25, 2018 4:39 AM EDT)
(updated to add analyst comment)
Goldman Sachs downgraded Biogen (NASDAQ: BIIB) from Conviction Buy to Buy with a price target of $388.00 (from $396.00).
Analyst Terrance Flynn remains Buy-rated after removing the name from the Conviction Buy... More
Biogen (BIIB) PT Lowered to $353 at Piper Jaffray
April 24, 2018 1:30 PM EDTPiper Jaffray lowered its price target on Biogen (NASDAQ: BIIB) to $353.00 (from $407.00) while maintaining a Overweight rating.
Analyst Chris Raymond comments "Remain Overweight rated on BIIB shares but also lowering estimates, price target after a Q118 top-line miss. Spinraza trends have... More
